Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AIM ImmunoTech Inc.
Report date April 04, 2022 · Filed January 03, 2023
Section 16 reporting ended · disclosed 2023-01-03. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 03, 2022 Filed Mar 4, 2022 15:11 UTC | AIM ImmunoTech Inc. AIM · Entity 8131 | GrantOptions · Derivative | 50,000 | $0.00 Strike: $0.70 | $0.00 |
DisclosureSEC source: 0001702626-22-000003 · primary_doc.xml · derivative · entry 1 LINTAL ELLEN M · CIK 0001788908 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-03-03 Read SEC document |
| November 30, 2021 Filed Nov 30, 2021 20:16 UTC | AIM ImmunoTech Inc. AIM · Entity 8131 | GrantOptions · Derivative | 100,000 | $0.00 Strike: $1.44 | $0.00 |
DisclosureSEC source: 0001788908-21-000002 · primary_doc.xml · derivative · entry 1 LINTAL ELLEN M · CIK 0001788908 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-11-30 Read SEC document |
| December 09, 2020 Filed Dec 11, 2020 14:19 UTC | AIM ImmunoTech Inc. AIM · Entity 8131 | GrantOptions · Derivative | 75,000 | $0.00 Strike: $1.85 | $0.00 |
DisclosureSEC source: 0001788908-20-000001 · primary_doc.xml · derivative · entry 1 LINTAL ELLEN M · CIK 0001788908 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2030-12-09 Read SEC document |
| December 31, 2019 Filed Jan 2, 2020 16:34 UTC | AIM ImmunoTech Inc. AIM · Entity 8131 | GrantCommon Stock | 3,931 | $0.53 | $2,083.43 |
DisclosureSEC source: 0001450324-20-000003 · primary_doc.xml · nonDerivative · entry 1 LINTAL ELLEN M · CIK 0001788908 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,892 F1 · kind: Common Stock Award. Vests in six months, provided continuous employment. Read SEC document |
| December 13, 2019 Filed Dec 16, 2019 15:07 UTC | AIM ImmunoTech Inc. AIM · Entity 8131 | GrantCommon Stock | 4,789 | $0.44 | $2,083.22 |
DisclosureSEC source: 0001450324-19-000030 · primary_doc.xml · nonDerivative · entry 1 LINTAL ELLEN M · CIK 0001788908 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,961 F1 · kind: Common Stock Award. Vests in six months, provided continuous employment. Read SEC document |
| November 29, 2019 Filed Dec 2, 2019 17:28 UTC | AIM ImmunoTech Inc. AIM · Entity 8131 | GrantCommon Stock | 5,208 | $0.40 | $2,083.20 |
DisclosureSEC source: 0001450324-19-000025 · primary_doc.xml · nonDerivative · entry 1 LINTAL ELLEN M · CIK 0001788908 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,172 F1 · kind: Common Stock Award. Vests in six months, provided continuous employment. Read SEC document |
| November 15, 2019 Filed Nov 18, 2019 20:07 UTC | AIM ImmunoTech Inc. AIM · Entity 8131 | GrantCommon Stock | 4,433 | $0.47 | $2,083.51 |
DisclosureSEC source: 0001450324-19-000020 · primary_doc.xml · nonDerivative · entry 1 LINTAL ELLEN M · CIK 0001788908 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,964 F1 · kind: Common Stock Award. Vests in six months, provided continuous employment. Read SEC document |
| October 31, 2019 Filed Oct 31, 2019 18:28 UTC | AIM ImmunoTech Inc. AIM · Entity 8131 | GrantCommon Stock | 4,167 | $0.50 | $2,083.50 |
DisclosureSEC source: 0001583701-19-000007 · primary_doc.xml · nonDerivative · entry 1 LINTAL ELLEN M · CIK 0001788908 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,531 F1 · kind: Common Stock Award. Vests in six months, provided continuous employment. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.